前列舒通胶囊联合爱普列特片治疗良性前列腺增生的疗效观察

目的探讨前列舒通胶囊联合爱普列特片治疗良性前列腺增生的临床疗效。方法选取2015年7月—2016年7月遵义医学院第五附属(珠海)医院进行治疗的90例良性前列腺增生患者,根据治疗方案的差别分为对照组(45例)和治疗组(45例)。对照组患者口服爱普列特片,5 mg/次,2次/d。治疗组在对照组的基础上口服前列舒通胶囊,3粒/次,3次/d。两组患者均连续治疗12周。治疗后,观察两组患者临床疗效,同时比较治疗前后两组患者IPSS和QOL评分、观察指标及不良反应情况。结果治疗后,对照组和治疗组的总有效率分别为80.00%、95.56%,两组比较差异具有统计学意义(P0.05)。治疗后,两组IPSS和QOL评分均明显减低,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组患者IPSS和QOL评分降低更明显,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者前列腺体积、残余尿量均显著减小,而最大尿流率明显增加,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组上述指标显著优于对照组,两组比较差异具有统计学意义(P0.05)。两组不良反应发生情况比较差异无统计学意义。结论前列舒通胶囊联合爱普列特片治疗良性前列腺增生效果显著,可明显改善患者临床症状及生活质量,具有一定的临床推广应用价值。

Clinical observation of Qianlie Shutong Capsules combined with Epristeride Tablets in treatment of benign prostatic hyperplasia

Objective To investigate the clinical efficacy of Qianlie Shutong Capsules combined with Epristeride Tablets in treatment of benign prostatic hyperplasia. Methods Patients (90 cases) with benign prostatic hyperplasia in the Fifth Affiliated (Zhuhai) Hospital of Zunyi Medical University from July 2015 to July 2016 were randomly divided into control (45 cases) and treatment groups (45 cases) based on different treatments. Patients in the control group were po administered with Epristeride Tablets, 5 mg/time, twice daily. Patients in the treatment group were po administered with Qianlie Shutong Capsules on the basis of the control group, three grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated; IPSS and QOL scores, observational indexes, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.00% and 95.56%, respectively, and there was difference between two groups (P < 0.05). After treatment, IPSS and QOL scores in two groups significantly decreased, the difference was statistically significant in the same group (P < 0.05). And the scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, prostate volume and residual urine volume was significantly decreased, while the maximum urinary flow rate was significantly increased, and the difference was statistically significant in the same group (P < 0.05). And those indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). There were no adverse reactions in two groups.Conclusion Qianlie Shutong Capsules combined with Epristeride Tablets has significant therapeutic effect in treatment of benign prostatic hyperplasia, can significantly improve the clinical symptoms and quality of life, which has a certain clinical application value of clinical application.